SBIR-STTR Award

Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions
Award last edited on: 11/13/2019

Sponsored Program
STTR
Awarding Agency
NIH : NIGMS
Total Award Amount
$1,829,208
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Jon O Nagy

Company Information

NanoValent Pharmaceuticals Inc

351-B Evergreen Drive
Bozeman, MT 59715
   (406) 586-8420
   N/A
   www.nanovalent.com

Research Institution

Children’s Hospital Los Angeles

Phase I

Contract Number: 1R41GM116530-01A1
Start Date: 2/1/2016    Completed: 1/31/2017
Phase I year
2016
Phase I Amount
$238,728
?The long-term goal of this Phase I STTR project is to develop a commercially viable ultrasound contrast reagent (UCR) that will allow the noninvasive identification of newly forming abdominal adhesions after surgery. Successful implementation would have significant impact because we would remove the impediment to clinical testing of anti-adhesion therapies, and at the same time would improve patient post-surgical monitoring in general. Although surgical adhesions have "fallen under the radar" when it comes to public perception, their heavy impact on the United States health care system is undeniable. Roughly 7 million abdominal surgical procedures of all types are carried out annually, and almost 100% of these patients will develop adhesions. While most are asymptomatic, a significant number can lead to serious and even life- threatening complications. This investigation will build on preliminary findings using the same targeting approach to adhesions that has already proven useful in fluorescent contrast reagents. To successfully bring adhesion imaging into a clinically relevant format the aims therefore include first synthesis and characterization of a polymer-stabilized, adhesion-targeted, ultrasound microbubble, followed by testing refinements in a relevant cell culture model. The successful targeted UCR formulations will then be examined in a limited number of animals to determine adhesion recognition and ultimately detection by non-invasive ultrasound interrogation. While the Phase I studies described here will be conducted using a well-characterized rat surgical adhesion model, our long-term aim is to develop UCRs that can image fibrinous "protoadhesions" in surgical patients. This product would not only allow the early alleviation of potentially problematic adhesions, but also overcome the main barrier to the testing and development of adhesion prevention therapies. Due to the huge magnitude of the problem, even a 50% reduction in post-surgical adhesions could save over $2.5 billion yearly in healthcare costs.

Public Health Relevance Statement:


Public Health Relevance:
This project seeks to develop a commercially viable ultrasound contrast reagent (UCR) that will allow the noninvasive identification of newly forming abdominal adhesions (deposits of fibrous scar tissue) after surgery. Successful implementation would have significant impact because we would remove the impediment to clinical testing of anti-adhesion therapies, and at the same time would improve patient post-surgical monitoring in general.

Project Terms:
Abdomen; Abdominal Surgical Procedures; Acoustics; Adhesions; Animal Model; Animals; base; Biocompatible Materials; Cell Culture Techniques; Cicatrix; Clinic; Clinical; clinically relevant; Contrast Media; Deposition; Development; Diagnostic; Early Intervention; Engineering; Evaluation; falls; Fibrin; Formulation; Future; Goals; Greater sac of peritoneum; Health Care Costs; Healthcare Systems; Hospitals; Human; Image; imaging modality; imaging system; Imaging technology; improved; In Vitro; in vivo imaging; Investigation; Laboratory Animals; Lead; Life; Liposomes; Medical; Membrane; Microbubbles; Modeling; Monitor; Non-Invasive Cancer Detection; novel; operation; Operative Surgical Procedures; Patients; Peptides; Perception; Phase; phase 1 study; Polymers; Prevention; Prevention therapy; Procedures; public health relevance; Rattus; Reagent; Research; research clinical testing; Safety; Science; Scientist; Second Look Surgery; Small Business Technology Transfer Research; small molecule; Specificity; success; Surgical Models; Synthesis Chemistry; Technology; Testing; Time; Tissues; Treatment Cost; Ultrasonography; United States

Phase II

Contract Number: 2R44GM116530-02
Start Date: 2/1/2016    Completed: 8/31/2020
Phase II year
2018
(last award dollars: 2019)
Phase II Amount
$1,590,480

The long-term goal of this Phase II SBIR project is to develop a commercially viable ultrasound contrast reagent (UCR) that will allow the noninvasive identification and treatment of newly forming abdominal adhesions after surgery. Successful implementation would have significant impact because we would both improve patient post-surgical monitoring and considerably reduce the cost of adhesion related pathology on the health care system. Although surgical adhesions have ?fallen under the radar? when it comes to public perception, their heavy impact on the United States health care system is undeniable. Roughly 7 million abdominal surgical procedures of all types are carried out annually, and almost 100% of these patients will develop adhesions. While most are asymptomatic, a significant number can lead to serious and even life-threatening complications. This Phase II investigation will build on our promising Phase I results defining a targeted polymerized shell microbubble (PSM) approach to imaging and treating adhesions. To successfully bring our technology closer to being commercially viable the aims include first optimizing and further characterizing our polymer-stabilized, adhesion-targeted, ultrasound microbubble model, followed by expanding our initial in vivo experiments to confirm their viability in both small and large animals. In our final aim, we intend to better understand and confirm our Phase I result in which we could show adhesion break-up in our rat model combining our targeted PSMs with non-invasive ultrasound irradiation. These further studies can confirm the viability of our technology moving it towards eventual clinical trials and commercial viability. This product would not only allow the early alleviation of potentially problematic adhesions, but also allow better monitoring of adhesion development and post-surgical recovery. Due to the huge magnitude of the problem, even a 50% reduction in post-surgical adhesions could save over $2.5 billion yearly in healthcare costs. !

Thesaurus Terms:
Abdomen; Abdominal Surgical Procedures; Acoustics; Address; Adhesions; Animal Model; Animals; Binding; Biocompatible Materials; Cicatrix; Clinical; Clinical Diagnostics; Clinical Trials; Clinical/Radiologic; Commercialization; Cost; Crosslink; Custom; Cytolysis; Deposition; Detection; Development; Diagnosis; Effectiveness; Engineering; Ensure; Ethics; Evaluation; Experimental Study; Fibrin; Formulation; Gases; Goals; Health Care Costs; Healthcare Systems; Hospitals; Image; Improved; In Vitro; In Vivo; Intervention; Investigation; Irradiation; Knowledge; Lead; Life; Lipids; Membrane; Methods; Microbubbles; Modeling; Monitor; Operation; Operative Surgical Procedures; Pathology; Patients; Perception; Peritoneal Fluid; Phase; Polymers; Population; Postoperative Period; Prevention; Procedures; Process; Production; Rattus; Reagent; Recovery; Reproducibility; Response; Scaffold; Science; Scientist; Second Look Surgery; Small Business Innovation Research Grant; Success; Synthesis Chemistry; System; Targeted Imaging; Techniques; Technology; Testing; Therapeutic; Tissues; Treatment Cost; Ultrasonic Therapy; Ultrasonography; United States; Work;